Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2

Bone Marrow Transplantation

Volumn 20, Issue 11, 1997, Pages 983-987

  Przepiorka, D ^a,d   Jaeckle, K A ^b   Birdwell, R R ^c   Fuller, G N ^a   Kumar, A J ^a   Huh, Y O ^a   McCutcheon, I ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c NONE

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Interleukin 2; JC virus; Progressive multifocal leukoencephalopathy; Treatment

Indexed keywords

INTERLEUKIN 2; PROTEIN P53;

ADULT; APHASIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CASE REPORT; FEMALE; HEMIPARESIS; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; JC VIRUS; LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VERTIGO;

EID: 0030726855     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701010     Document Type: Article

References (11)

1. Arthur RR, Shah KV, Charache P, Saral R. BK and JC virus infections in recipients of bone marrow transplants. J Infect Dis 1988; 158: 563-569.
2. Assi A, Fanci R, Bosi A et al. Monitoring of polyomavirus BK viruria in bone marrow transplantation patients by DNA hybridization assay and by polymerase chain reaction: an approach to assess the relationship between BK viruria and hemorrhagic cystitis. Bone Marrow Transplant 1994; 14: 235-240.
3. Berger JR, Kaszovitz B, Post JD, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. Ann Intern Med 1987; 107: 78-87.
4. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124: 633-642.
5. Ariza A, Mate JL, Fernandez-Vasalo A et al. p53 and proliferating cell nuclear antigen expression in JC virus-infected cells of progressive multifocal leukoencephalopathy. Human Pathol 1994; 25: 1341-1345.
6. Cayeux S, Meuer S, Pezzutto A et al. Allogeneic mixed lymphocyte reactions during a second round of ontogeny: normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogenous IL-2. Blood 1989; 74: 2278-2284.
7. Gottlieb DJ, Prentice HG, Heslop HE et al. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematologic malignancy. Blood 1989; 74: 2335-2342.
8. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-2568.
9. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517-526.
10. Chang C-F, Otte J, Kerr DA et al. Evidence that the soluble factors secreted by activated immune cells suppress replication of human neurotropic JC virus DNA in glial cells. Virology 1996; 221: 226-231.
11. Heslop HE, Gottlieb DJ, Bianchi ACM et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374-1380.